– USA, MA – Harbour BioMed (HKEX: 02142), a global biopharmaceutical company, today announced the appointment of Dr. Albert Collinson (Ph.D.) to its Board as an Independent Non-Executive Director.
“I am delighted to welcome Dr. Collinson to Harbour BioMed. His scientific background combined with extensive experience in business will be invaluable to enhance our ability to achieve goals and fuel Harbour BioMed’s future growth,” said Chairman and CEO, Dr. Jingsong Wang.
About Dr. Albert R. Collinson
Dr. Collinson has over 30 years of experience in the pharmaceutical and biotechnology industries. He has been the president and CEO at Theracos, Inc. since July 2009, a pharmaceutical research and development company focusing on mid- to late-stage assets for the treatment of human diseases including type-2 diabetes. Before this appointment at Harbour BioMed, Dr. Collinson founded and served as president and CEO of Opsonic Therapeutics from 2009 to June 2014, a privately held biotechnology company engaged in the development of the next generation of antibody therapeutics. Dr. Collinson also served as CBO of Rib-X Pharmaceuticals from 2004 to 2009, SVP of business development at Phylos, Inc. from 2000 to 2004, and VP of global research & development licensing at BASF Pharma from 1998 to 2000. Dr. Collinson began his career as a scientist at ImmunoGen, Inc.
“Harbour BioMed is a company that has demonstrated a strong commitment to the development of next-generation therapeutics and innovations. In recent years, the company has achieved great success in portfolio development and efficient business operations. I am proud to have joined the Board of Directors and look forward to contributing to the Company’s next phase of growth, which will be driven by its enhanced global strategy.” said Dr. Collinson.
Dr. Collinson received his Ph.D. in Biochemistry from Brandeis University in 1987 and his bachelor’s degree in science in Biology (General) from the University of Rhode Island in 1980. Dr. Collinson was a post-doctoral fellow at the Dana Farber Cancer Institute and Harvard Medical School.
About Harbour BioMed
Harbour BioMed is a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on immunology and oncology. The Company is building its robust portfolio and differentiated pipeline through internal R&D capability, collaborations with co-discovery and co-development partners, and select acquisitions.
The Company’s proprietary antibody technology platform Harbour Mice generates fully human monoclonal antibodies in two heavy and two light chain formats, as well as a heavy chain-only format. Building upon the HCAb antibodies, the HCAb-based immune cell engagers bispecific antibody technology is capable of delivering tumor-killing effects unachievable by traditional combination therapies. Integrating Harbour Mice, and HBICE with a single B cell cloning platform, our antibody discovery engine is highly unique and efficient for the development of next-generation therapeutic antibodies.
SOURCE: https://www.harbourbiomed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
